Melanoma patients treated with a combination of T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have developed immune-related adverse events (irAEs) of grade three or higher [93]. The gene discussed is PDCD1; the disease is melanoma.